David McIntosh: How European Plasma Policy Shapes Global Access to Life-Saving Therapies
David McIntosh, Founder and Chair of United Plasma Action, shared Expresso’s post on LinkedIn:
“This excellent post highlights a stubborn problem that has afflicted the European Union throughout this Century – doing great damage, not only to European Healthcare but to Healthcare globally.
In the field of vital plasma-derived medicines (of which there’s a fatal global shortage)
European institutions lounge luxuriously in a self-important but utterly delusional feeling of superior morality, based on pseudo-ethical notions about the sanctity of ‘Substances of Human Origin‘.
Less self-indulgent philosophers recognize that the important thing about life-saving plasma-derived medicines is not their origin, but their destination.
They are produced for one purpose and for one purpose only – to provide patients with the treatments they need.
All over the World, rare disease sufferers are going through untold trauma and succumbing to an early death, simply due to a lack of plasma-derived medicines.
One would sincerely expect therefore that every Healthcare organization in the World would be doing its best to help increase the global plasma harvest – but what is Europe doing … ?
For instance …
- what is the EU doing?
- what is it’s SUPPLY team doing?
- what is the European Blood Alliance doing?
- what contribution is being made by the International Plasma and Fractionation Association?
The sad fact is that they are all misguidedly inhibiting progress towards improving the plasma harvest, both in Europe and globally – to the deep detriment of patients everywhere – detriment and death.
That’s what’s genuinely unethical.
It really does have to stop.”
Expresso shared a post on LinkedIn:
“Fragility.
Portugal spends 100 million euros a year on medicines made from plasma and imports 89 percent of the raw material, mainly from the USA.
Experts warn of the ethical, financial and geopolitical risks of this insufficiency.
Read more.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?
-
Nov 17, 2026, 23:38Amos Gitonga Mbaabu: Strengthening Care and Advocacy for Haemophilia and SCD across Southern Africa
-
Nov 17, 2026, 23:35Muhammad Sameed Altaf: A Decade of Working Together for Thalassemia Awareness and Patient Support
-
Nov 17, 2026, 23:34Ahmed Bennis: Is Aspirin Therapy Enough for VTE Prevention After Arthroplasty?
-
Nov 17, 2026, 23:33Remi Remakanth: The Role of Transfusion Medicine in HLA Antibody Testing and Transplant Desensitization